Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
Conditions
Advanced Non-small Cell Lung Cancer - First Line Treatment - Thioredoxin Reductase Activity - Carcinoembryonic Antigen - Progression
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
non-small cell lung cancer, thioredoxin reductase
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Prospective
Overall Status
Recruiting
Summary
In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after any kind of treatment serum thioredoxin reductase activity declined remarkably, so we hypothesis that serum thioredoxin reductase activity could be a warning marker for early progression of first-line treatment for advanced non-small cell lung cancer
Detailed Description
This is a cooperative research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University, and the State Key Laboratory for Natural Medicine and Biomimetic Drugs Perking University. The primary objective is to measure the thioredoxin reductase activity using blood in subjects received platinum based chemotherapy, to study the warning progression ability of thioredoxin reductase in blood. The secondary objective is to compare the warning progression activity of blood thioredoxin reductase reductase activity with carcinoembryonic antigen in subjects received platinum based first-line chemotherapy. Blood will be collected before chemotherapy, after every 2 cycles of chemotherapy, every 3 months after all first-line chemotherapy till 2 years, then every 6 months till 3 years, or collect blood till tumor progression, evaluation CT results every time collecting blood samples.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Pathologically proven non-small cell lung cancer, stage Ⅳ patients or unsuitable for local treatment of ⅢB stage patients

- Malignant tumor treatment naive including surgery(except for surgery for cervical cancer and cutaneous squamous cell carcinoma 5 years before, except for lung cancer patients who received surgery and adjuvant chemotherapy after 12 month then diagnosed with stage ⅢB or Ⅳ)

- Signed informed consent would like to provide blood for research

Exclusion Criteria:

- Patients received antitumor treatment before

- Patients with contraindication of chemotherapy

- Pregnant or breast feeding women
Location
Hunan Provincal Tumor Hospital
Changsha, Hunan, China
Status: Recruiting
Contact: Nong Yang, MD - +86 731 89762323 - yangnong0217@163.com
Start Date
May 2013
Completion Date
December 2016
Sponsors
Hunan Province Tumor Hospital
Source
Hunan Province Tumor Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page